# Angiodynamics Inc: Form 10-Q for the period ended Aug 31, 2014

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2014-10-15
- Accepted by EDGAR: Oct 15, 2014, 17:30 ET
- Period: 2014-08-31
- Accession: 0001445305-14-004301
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000144530514004301/ango-083114x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000144530514004301/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-08-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-06-01 to 2014-08-31 | $87.3m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2014-06-01 to 2014-08-31 | $41.5m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2014-06-01 to 2014-08-31 | $45.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2014-06-01 to 2014-08-31 | $6.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2014-06-01 to 2014-08-31 | $3.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-06-01 to 2014-08-31 | $799.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2014-06-01 to 2014-08-31 | $948.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-06-01 to 2014-08-31 | $470.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-06-01 to 2014-08-31 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-06-01 to 2014-08-31 | $0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2014-06-01 to 2014-08-31 | 35,885,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 3 months, 2014-06-01 to 2014-08-31 | $5.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2014-08-31 | $13.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-08-31 | $154.3m | us-gaap:AssetsCurrent |
| Total assets | at 2014-08-31 | $796.1m | us-gaap:Assets |
| Current liabilities | at 2014-08-31 | $63.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-08-31 | $256.4m | us-gaap:Liabilities |
| Current portion of debt | at 2014-08-31 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2014-08-31 | $539.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 17,595 characters.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

### Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC, including our Form 10-K for the fiscal year ended May 31, 2014.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

### Overview

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use.

We sell our products in the United States through a direct sales force and outside the U.S. through a combination of direct sales and distributor relationships. For the three months ended August 31, 2014 and 2013, approximately 20% and 18%, respectively, of our net sales were from markets outside the United States.

Our sales and profitability growth depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. In recent years we have acquired or developed, and launched several new products, including the AngioVac cannula and circuit, the BioFlo family of products, and the Acculis microwave system, which are all expected to be growth drivers of our business. We recognize the importance of, and intend to continue to make investments in, research and development activities and business development opportunities.

Our ability to further increase our profitability will depend in part on improving gross profit and operating margins. A portion of improved gross margin we expect to deliver through the acquisition, development and sale of innovative products, such as those mentioned above. Additionally, in December 2013 we announced a company-wide operational excellence program designed to create greater efficiencies and drive improved business performance. Further, we anticipate being able to manage increases in our operating expenses at a rate slower than our sales growth to provide further operating margin expansion.

### Immaterial Error Corrections

During the financial closing process for the first quarter of fiscal year 2015, the Company determined that financial management had incorrectly accounted for certain asset, liability and income statement balances, beginning in 2011. The Company has identified amounts and concluded that they were not material individually or in the aggregate to any of its previously issued annual and interim financial statements. Although management has determined the amounts individually and in the aggregate are not material to prior periods, in accordance with authoritative accounting literature on considering the effects of misstatements in prior years when quantifying misstatements in the current year, the financial statements included herein have been adjusted to correct for the impact of these items.

The Company has corrected the relevant financial information from previous reporting periods contained in these financial statements. The immaterial error corrections identified were primarily related to our failure to recognize the expense associated with prepaid and other assets in accordance with the underlying contractual terms (cumulative impact of approximately $1.2 million) and depreciation expense (cumulative impact of approximately $0.4 million), and other individually immaterial items.

### New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note N to our consolidated financial statements in this Quarterly Report on Form 10-Q.

### Results of Operations for the Three Months ended August 31, 2014 and August 31, 2013

For the three months ended August 31, 2014, we reported net income of $470 thousand, or $0.01 per diluted share, on net sales of $87.3 million, compared with a net loss of $373 thousand, or $(0.01) per share, on net sales of $83.6 million during the same quarter of the prior year.

The table below presents certain operating data as a percentage of net sales:

|  | Three Months Ended Aug 31, 2014 | Aug 31, 2013 As revised |
| --- | ---: | ---: |
| Net sales | 100.0% | 100.0% |
| Gross profit | 52.5% | 50.9% |
| Research and development | 7.7% | 8.0% |
| Sales and marketing | 23.0% | 23.9% |
| General and administrative | 8.4% | 8.0% |
| Amortization of intangibles | 4.6% | 4.9% |
| Change in fair value of contingent consideration | 0.9% | 0.9% |
| Acquisition, restructuring and other items, net | 3.1% | 2.4% |
| Medical device excise tax | 1.1% | 1.2% |
| Operating income | 3.7% | 1.7% |
| Other income (expenses) | (2.1)% | (2.3)% |
| Income taxes | 1.1% | (0.2)% |
| Net income (loss) | 0.5% | (0.4)% |

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns. For the three months ended August 31, 2014, net sales increased $3.7 million to $87.3 million when compared to the same period in the prior year. This increase was primarily attributable to increased product sales of the AngioVac; Nanoknife; microwave, and the Bioflo family of products, partially offset by decreased sales of RFA, and products sold through our supply agreement arrangement.

From a product line perspective, Peripheral Vascular sales increased $1.7 million or 3.8% from the prior year period to $47.3 million. This increase was primarily attributable to the AngioVac product line. Vascular Access sales were $26.5 million, an increase of $1.2 million or 4.9% from the prior year period. This increase is attributable to increased sales of our port products. Oncology/Surgery sales were $12.4 million, an increase of 10.8% from prior year quarter sales of $11.2 million, primarily due to increased sales of our microwave and NanoKnife products partially offset by decreased RFA sales.

From a geographic perspective, U.S. sales increased $1.4 million or 2.1% during the first three months of fiscal 2015 to $68.6 million when compared to the same period in the prior year. This increase was primarily attributable to increased sales of AngioVac, port products, microwave and NanoKnife products, partially offset by RFA decreases. International sales were $17.6 million in the fiscal first quarter of 2015, an increase of 18.6% from $14.8 million in the comparable prior year period. The increase is attributable to increased sales of fluid management, microwave and Nanoknife. Our supply agreement arrangement, which we do not include in either the U.S. or International geographic sales, declined 28.3% to $1.2 million from $1.6 million in the prior year period.

Changes in sales are driven primarily by increases in volume.

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. Our gross profit as a percentage of sales increased from 50.9% in the prior year period to 52.5% during the three months ended August 31, 2014. The increase is largely attributable to improved operating efficiencies and mix of products sold.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs and our intellectual property. For both the three months ended August 31, 2014 and 2013, R&D expenses were $6.7 million. As a percentage of net sales, R&D expenses were 7.7% and 8.0% for the first quarters of fiscal years 2015 and 2014, respectively.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. S&M expenses increased $0.1 million during the three months ended August 31, 2014 to $20.1 million when compared to the same period in the prior year. As a percentage of net sales, S&M expenses decreased to 23.0% in the fiscal first quarter of 2015, from 23.9% for the prior year period.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance and accounting, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expenses increased $0.6 million, or 9.5%, to $7.3 million when compared to the same period in the prior year. G&A expenses increased to 8.4% of net sales from 8.0% in the prior year period. The increase is primarily a result of costs associated with the implementation of our ERP system.

Amortization of intangibles - Amortization of intangibles decreased $0.1 million to $4.0 million during the period.

Change in fair value of contingent consideration - The first quarter of fiscal 2015 included accretion of $0.8 million in the change in fair value of the contingent consideration associated with the Vortex, Microsulis and Clinical Devices acquisitions compared with $0.7 million in the prior year period.

Acquisition, restructuring and other items, net - The first quarter of fiscal 2015 included Acquisition, restructuring and other items, net expenses of $2.7 million compared to $2.0 million in the prior year period, which primarily consisted of $1.1 million of severance expense related to the reorganization of our R&D and S&M workforce, $0.8 million of costs related to our operational excellence program and $0.8 million of litigation expense and other items.

Medical device excise tax - The first quarter of fiscal 2015 and 2014 included $1.0 million of expense attributed to Medical Device Excise Tax enacted into law effective January 1, 2013.

Operating income - During the three months ended August 31, 2014, operating income increased $1.8 million to $3.2 million. As a percentage of sales, operating income was 3.7% and 1.7% for the three months ended August 31, 2014 and 2013, respectively.

Other expenses - Other expenses for the three months ended August 31, 2014 and 2013 were $1.8 million and $2.0 million, respectively.

Income taxes - Our effective tax rate including discrete items was 67% for the first fiscal quarter of 2015 compared with 34% effective tax rate for the prior year period. The current quarter reflects no benefit from the expired R&D tax credit. In addition, our ASC 718 APIC pool was fully depleted in the quarter ended February 28, 2014. Prior to its depletion, the APIC pool was reduced when share-based compensation cost previously recognized was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting. Due to its depletion, we recorded a discrete tax expense of $354 thousand in the three months ended August 31, 2014.

The prior year period reflects a seven month benefit from the R&D tax credit that had previously expired on December 31, 2013 and a benefit from lower tax rates applicable to our foreign operations, partially offset by non-deductible interest expense on contingent payments.

Net income (loss) - For the three months ended August 31, 2014, we reported net income of $0.5 million, compared to a net loss of $0.4 million for the same period in the prior year.

### Liquidity and Capital Resources

Our cash and cash equivalents totaled $13.8 million as of August 31, 2014, compared with $16.1 million as of May 31, 2014. Marketable securities totaled $1.7 million and $1.8 million as of August 31, 2014 and May 31, 2014, respectively, and consist of auction rate securities. As of August 31, 2014, total debt was $141 million primarily comprised of short and long-term bank debt. The fair value of contingent milestone payments as of August 31, 2014 was $66 million.

The table below summarizes our cash flows for the three months ended August 31, 2014 and 2013 (in thousands of dollars):

| Cash provided by (used in): | Three Months Ended Aug 31, 2014 | Aug 31, 2013 As revised |
| --- | ---: | ---: |
| Operating activities | $5,352 | $7,300 |
| Investing activities | (5,258) | (6,769) |
| Financing activities | (2,391) | (272) |
| Effect of exchange rate changes on cash and cash equivalents | — | 4 |
| Net change in cash and cash equivalents | $(2,297) | $263 |

Net cash provided by operating activities during the three months ended August 31, 2014 and 2013 was $5.3 million and $7.3 million, respectively. Cash provided by operating activities during the three months ended August 31, 2014, was primarily the result of an increase of $1.5 million in tax deferrals, increases in non cash expenses such as depreciation and amortization and share based compensation in the three month period ended August 31, 2014 compared to the prior year period. During the quarter ended August 31, 2014 we experienced cash outflows due to increased inventories and prepaid expenses coupled with a reduction in accounts payable and accrued liabilities partially offset by a decrease in accounts receivable.

Net cash used in investing activities during the three months ended August 31, 2014 and 2013 was $5.3 million and $6.8 million, respectively. The net cash used in investing activities for the current year period consisted primarily of fixed asset additions. The prior year period use of cash consisted primarily of the Clinical Devices acquisition and fixed asset additions.

Net cash used in financing activities during the three months ended August 31, 2014 and 2013 was $2.4 million and $0.3 million, respectively. The current year period consisted primarily of a scheduled debt payment and payment of contingent consideration related to the acquisition of Microsulis, partially offset by proceeds from the exercise of stock options and purchases related to our employee stock purchase plan.

Our contractual obligations and their effect on liquidity and cash flows have not changed substantially from that disclosed in our Annual Report on Form 10-K for our fiscal year ended May 31, 2014.

We believe that our current cash and investment balances, together with cash generated from operations and our remaining revolving credit facility capacity of $53.6 million as of August 31, 2014, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future for cash, we may require external financing.

## Market risk

As filed, 2,068 characters.

We are exposed to market risk from changes in interest rates on investments and financing that could impact our results of operations and financial position. Although we have entered into interest rate swaps with a bank to limit our exposure to interest rate change on our variable interest rate financings, we do not currently engage in any other hedging or market risk management tools.

Nearly all of our sales have historically been denominated in United States dollars. Although not significant, we transact sales in other currencies, particularly the Euro, GB pound and Canadian dollar. We currently have no significant direct foreign currency exchange risk.

Our excess cash is invested in highly liquid, short-term, investment grade securities with maturities primarily of less than two years. These investments are not held for speculative or trading purposes. Changes in interest rates may affect the investment income we earn on cash, cash equivalents and marketable securities and therefore affect our cash flows and results of operations. We hold investments in auction rate securities (“ARS”) in order to generate higher than typical money market investments. ARS typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids. Such instances are usually the result of a drastic deterioration of issuer credit quality. Should there be a failed auction, we may be unable to liquidate our position in the securities in the near term. We have $1.7 million in investments in two auction rate securities issued by New York state and local government authorities that have failed auctions. The authorities are current in their interest payments on the securities.

We are party to legal actions that arise in the ordinary course of business. (See Note M of Notes to Consolidated Financial Statements for more information related to legal actions.)

## Controls and procedures

As filed, 6,464 characters.

### Evaluation of disclosure controls and procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based solely on the definition of "disclosure controls and procedures" in Rule 13a-15(e) promulgated under the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision of our Company’s Chief Executive Officer and Chief Financial Officer, we carried out an evaluation of our disclosure controls and procedures as of August 31, 2014. At the time our Annual Report on Form 10-K for the year ended May 31, 2014 was filed on August 14, 2014, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of May 31, 2014. Subsequent to that evaluation, in assessing the control deficiencies that contributed to the immaterial error corrections described in Note A and Note P which were identified during our financial close process for the period ended August 31, 2014, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of May 31, 2014 and August 31, 2014 because of the material weaknesses in our internal control over financial reporting described below.

A material weakness is a deficiency, or a combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

*We did not maintain effective controls over the preparation, review and approval of certain account reconciliations. Specifically, the Company did not maintain effective controls over the completeness and analysis of supporting schedules and underlying data supporting account reconciliations prepared for certain prepaid expenses and other assets and fixed assets and accumulated depreciation.*

*We lacked a sufficient complement of personnel with a level of financial reporting expertise commensurate with our financial reporting requirements, specifically, with respect to resources capable of monitoring and accurately recording certain routine transactions specifically in prepaid expenses and other assets and fixed assets and accumulated depreciation, to effectively perform testing related to our ERP implementation specifically associated with the configuration of certain intercompany transactions and the conversion of data related to depreciation, or to properly perform account reconciliations as noted above.*

These material weaknesses resulted in the revision to our previously reported interim and annual financial statements for the fiscal year ended May 31, 2014 and for the fiscal years ended May 31, 2013, 2012, and 2011, as described in Note P of this Quarterly Report. Accordingly, the Company will be amending its Annual Report on Form 10-K for the year ended May 31, 2014 to reflect the conclusion by the Company's management that internal control over financial reporting and disclosure controls and procedures were not effective as of May 31, 2014.

These material weaknesses could result in misstatements that would result in a material misstatement of the consolidated financial statements that would not be prevented or detected.

In response to these material weaknesses, our management performed additional analysis and procedures, including enhanced business performance reviews and analysis, in order to conclude that despite the material weaknesses reported above, the consolidated financial statements included in this report fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods presented and that this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

### Remediation Plan

During the quarter ended August 31, 2014, we developed a plan to enhance our internal controls over financial reporting, which we believe also will address the material weaknesses discussed above, including the specific remediation initiatives described below:

- Enhancing our internal finance and accounting organizational structure, which includes changes to personnel in place as of May 31, 2014 and hiring additional resources.
- Strengthening our internal policies and processes, including training for personnel, for ensuring account reconciliations are completed and reviewed properly.
- Continued investments in our ERP to improve the transactional accounting and processes supporting the recording of certain routine transactions.

As part of this plan, the following steps were taken during our first quarter of our fiscal year ended May 31, 2015:

- Hired additional full-time and temporary accounting resources with appropriate levels of experience, including a new Global Controller to drive improvement of and oversee day-to-day accounting activities.
- Commenced a detailed review of our ERP to identify opportunities to improve the accuracy of routine transaction processing, specifically with respect to accounting transactions related to purchasing and payables.

### Changes in Internal Control over Financial Reporting

Other than items described above related to steps taken under our remediation plan during the quarter, there was no change in our internal control over financial reporting in the fiscal quarter ended August 31, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,985 characters.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2014 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K, except for the following related to our internal controls:

**We have determined that material weaknesses exist in our internal control over financial reporting which could, if not remediated, have a material adverse impact on our ability to produce timely and accurate financial statements.**

We are responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act. As discussed in Part I - Item 4, we identified material weaknesses in our internal control over financial reporting as of May 31, 2014. Solely as a result of these material weaknesses, management concluded that our internal control over financial reporting was not effective as of May 31, 2014.

A material weakness is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Although we continue to devote significant time and attention to remedy the identified material weaknesses in internal control over financial reporting, we expect to complete our remediation plan and testing of the remediated controls during the fiscal year ended May 31, 2015. There is the potential that our remedial efforts may not be successful. Until our remediation plan is fully implemented, our management will continue to devote significant time and attention to these efforts. If we do not complete our remediation in a timely fashion, or at all, or if our remediation plan is inadequate or we encounter difficulties in the implementation or maintenance of our internal control over financial reporting or disclosure controls and procedures, there will continue to be an increased risk that we will be unable to timely file future periodic reports with the SEC and/or remain in compliance with certain covenants included in our outstanding debt agreements. In addition, any failure to implement or any difficulties we encounter with our remediation plan could result in additional material weaknesses or deficiencies in our internal control or future material misstatements in our annual or interim consolidated financial statements.

Filed Oct 15, 2014.
Source: SEC EDGAR, the filing index for accession 0001445305-14-004301. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
